Sun Pharmaceutical Industries Ltd announced that the USFDA has approved its drug LEQSELVI (deuruxolitinib) for treating adults with severe alopecia areata. The approval is based on Phase 3 clinical trials involving 1,220 patients. LEQSELVI provides a new treatment option for patients with significant hair loss due to this autoimmune disorder.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i9NwTQc
via IFTTT
No comments:
Post a Comment